Abstract
Clinical studies had found that hydrogen/oxygen mixed inhalation was beneficial to ameliorate the respiratory symptoms in the adjuvant treatment of patients with COVID-19. We aimed to explore the efficacy of hydrogen/oxygen therapy in favoring the recovery of Omicron SARS-CoV-2 variant infection. There were 64 patients who randomly assigned to receive hydrogen/oxygen inhalation (32 patients) and oxygen inhalation (32 patients). The average shedding duration of Omicron in hydrogen/oxygen group was shorter than oxygen group. The trend of cumulative negative conversion rate of Omicron increased gradually after the third day. The IL-6 levels in hydrogen/oxygen group decreased by 22.8% compared with the baseline. After hydrogen/oxygen mixed gas inhalation, the lymphocyte count increased to 61.1% of the baseline on the 3rd day in the hydrogen/oxygen group. More patients in the hydrogen/oxygen group had resolution of pulmonary lesions. Our study showed the beneficial trends of molecular hydrogen in treating patients with COVID-19, which may offer a prospective solution to adjuvant therapy for COVID-19 Patients.
Introduction
The Omicron variant of SARS-CoV-2, while often associated with less severe primary pneumonia than earlier strains, remains a significant clinical challenge due to its high transmissibility and potential to trigger hyper-inflammatory responses, often referred to as a "cytokine storm." Molecular hydrogen ($H_2$) has emerged as a potential therapeutic agent due to its potent antioxidant and anti-inflammatory properties. Previous research indicated that $H_2/O_2$ mixed inhalation could improve airway resistance and ameliorate symptoms in patients with COPD or earlier COVID-19 strains. This study investigates whether hydrogen therapy can serve as an effective adjuvant treatment to accelerate viral clearance and mitigate lung damage specifically in patients infected with the Omicron variant.
Methods
This prospective, multicenter, randomized, controlled trial was conducted across seven hospitals in China.
- Participants: 64 patients with "common type" COVID-19 severity were enrolled and randomly assigned to two groups: the hydrogen/oxygen group ($n=32$) and the oxygen control group ($n=32$).
- Intervention: The treatment group received a hydrogen/oxygen gas mixture (66.6% $H_2$ and 33.3% $O_2$) at a flow rate of 3 L/min via nasal cannula for at least 7 hours daily. The control group received standard oxygen therapy.
- Evaluation: Clinical signs, laboratory markers (IL-6, lymphocyte counts), and chest CT scans were monitored. Viral shedding was tracked via daily PCR testing. Both groups received standard-of-care treatments, including antivirals like Paxlovid.
Results
Viral Clearance and Negative Conversion
The hydrogen/oxygen group demonstrated a trend toward faster viral clearance. The average duration of Omicron shedding was 3.3 days in the treatment group compared to 4.1 days in the control group. By day 5, 87.5% of the hydrogen group had achieved negative conversion, versus 75% in the oxygen group. By day 10, 100% of the hydrogen group had cleared the virus.
Inflammatory Response and Immune Support
A significant finding was the impact on Interleukin-6 (IL-6) levels. By day 3, IL-6 levels in the hydrogen group dropped by 22.8% from baseline, suggesting a mitigation of the hyper-inflammatory response. Furthermore, the hydrogen group showed a more robust recovery of lymphocyte counts, reaching 61.1% of baseline by day 3, which supports the maintenance of cellular defense mechanisms during infection.
Pulmonary Resolution
Radiological evidence from chest CT scans indicated that more patients in the hydrogen/oxygen group experienced significant resolution of pulmonary lesions (defined as >50% improvement) compared to the control group. This suggests that the antioxidant properties of $H_2$ may directly protect lung tissue from oxidative damage during the infection phase.
Discussion and Limitations
This trial suggests that $H_2/O_2$ inhalation is a safe and potentially effective adjuvant therapy for Omicron infection. The therapy appears to act by suppressing the cytokine storm (reducing IL-6), supporting immune cell recovery (lymphocytes), and facilitating physical lung repair.
However, the study was limited by a relatively small sample size ($n=64$), which may have underpowered the statistical significance of viral shedding duration despite the clear positive trend. Additionally, variations in enrollment timing relative to the initial infection may have impacted the precision of shedding data. Future large-scale trials are warranted to confirm these findings and further investigate the molecular pathways, such as the regulation of TLR4-mediated NF-κB signaling, through which hydrogen exerts its protective effects.
Summary updated